29 September 2017

Dr Sudhin Thayyil
R 529, Level 5, Hammersmith House
Academic Neonatology
W12 0HS

Dear Dr Thayyil

**Study title:** Genomic Imaging in Neonatal Encephalopathy (GENIE) study
**REC reference:** 17/SW/0212
**Protocol number:** 17HH4119
**IRAS project ID:** 233406

Thank you for your letter of 22 September 2017, responding to the Committee’s request for further information on the above research and submitting revised documentation.

The further information has been considered on behalf of the Committee by the Chair

We plan to publish your research summary wording for the above study on the HRA website, together with your contact details. Publication will be no earlier than three months from the date of this opinion letter. Should you wish to provide a substitute contact point, require further information, or wish to make a request to postpone publication, please contact hra.studyregistration@nhs.net outlining the reasons for your request.

**Confirmation of ethical opinion**

On behalf of the Committee, I am pleased to confirm a favourable ethical opinion for the above research on the basis described in the application form, protocol and supporting documentation as revised, subject to the conditions specified below.
Conditions of the favourable opinion

The REC favourable opinion is subject to the following conditions being met prior to the start of the study.

Management permission must be obtained from each host organisation prior to the start of the study at the site concerned.

Management permission should be sought from all NHS organisations involved in the study in accordance with NHS research governance arrangements. Each NHS organisation must confirm through the signing of agreements and/or other documents that it has given permission for the research to proceed (except where explicitly specified otherwise).


Where a NHS organisation’s role in the study is limited to identifying and referring potential participants to research sites (“participant identification centre”), guidance should be sought from the R&D office on the information it requires to give permission for this activity.

For non-NHS sites, site management permission should be obtained in accordance with the procedures of the relevant host organisation.

Sponsors are not required to notify the Committee of management permissions from host organisations

Registration of Clinical Trials

All clinical trials (defined as the first four categories on the IRAS filter page) must be registered on a publically accessible database within 6 weeks of recruitment of the first participant (for medical device studies, within the timeline determined by the current registration and publication trees).

There is no requirement to separately notify the REC but you should do so at the earliest opportunity e.g. when submitting an amendment. We will audit the registration details as part of the annual progress reporting process.

To ensure transparency in research, we strongly recommend that all research is registered but for non-clinical trials this is not currently mandatory.

If a sponsor wishes to request a deferral for study registration within the required timeframe, they should contact hra.studyregistration@nhs.net. The expectation is that all clinical trials will be registered, however, in exceptional circumstances non registration may be permissible with prior agreement from the HRA. Guidance on where to register is provided on the HRA website.

It is the responsibility of the sponsor to ensure that all the conditions are complied with before the start of the study or its initiation at a particular site (as applicable).

Ethical review of research sites

NHS sites

The favourable opinion applies to all NHS sites taking part in the study, subject to management
permission being obtained from the NHS/HSC R&D office prior to the start of the study (see "Conditions of the favourable opinion" below).

Non-NHS sites

**Approved documents**

The final list of documents reviewed and approved by the Committee is as follows:

<table>
<thead>
<tr>
<th>Document</th>
<th>Version</th>
<th>Date</th>
</tr>
</thead>
<tbody>
<tr>
<td>Evidence of Sponsor insurance or indemnity (non NHS Sponsors only) [Insurance]</td>
<td></td>
<td>24 July 2018</td>
</tr>
<tr>
<td>GP/consultant information sheets or letters [GP letter]</td>
<td>1.1</td>
<td>16 September 2017</td>
</tr>
<tr>
<td>IRAS Application Form [IRAS_Form_23082017]</td>
<td></td>
<td>23 August 2017</td>
</tr>
<tr>
<td>IRAS Checklist XML [Checklist_23082017]</td>
<td></td>
<td>23 August 2017</td>
</tr>
<tr>
<td>Letter from sponsor [Sponsor letter]</td>
<td></td>
<td>23 August 2017</td>
</tr>
<tr>
<td>Other [Consent form Parents]</td>
<td>1.1</td>
<td>16 September 2017</td>
</tr>
<tr>
<td>Other [Consent baby Tracked Changes]</td>
<td>1.1</td>
<td>16 September 2017</td>
</tr>
<tr>
<td>Other [Consent Parents Tracked Changes]</td>
<td>1.1</td>
<td>16 September 2017</td>
</tr>
<tr>
<td>Other [Participant Information Sheet Tracked Changes]</td>
<td>1.1</td>
<td>16 September 2017</td>
</tr>
<tr>
<td>Other [Protocol Tracked changes]</td>
<td>1.1</td>
<td>16 September 2017</td>
</tr>
<tr>
<td>Other [Response to REC panel]</td>
<td></td>
<td>22 September 2017</td>
</tr>
<tr>
<td>Participant consent form [Baby consent form]</td>
<td>1.1</td>
<td>16 September 2017</td>
</tr>
<tr>
<td>Participant information sheet (PIS) [PIS]</td>
<td>1.1</td>
<td>16 September 2017</td>
</tr>
<tr>
<td>Research protocol or project proposal [Protocol]</td>
<td>1.1</td>
<td>16 September 2017</td>
</tr>
<tr>
<td>Summary CV for Chief Investigator (CI) [CV]</td>
<td>1</td>
<td>01 August 2017</td>
</tr>
<tr>
<td>Summary CV for student [CV Montaldo]</td>
<td>1</td>
<td>01 August 2017</td>
</tr>
</tbody>
</table>

**Statement of compliance**

The Committee is constituted in accordance with the Governance Arrangements for Research Ethics Committees and complies fully with the Standard Operating Procedures for Research Ethics Committees in the UK.

**After ethical review**

**Reporting requirements**

The attached document “After ethical review – guidance for researchers” gives detailed guidance on reporting requirements for studies with a favourable opinion, including:

- Notifying substantial amendments
- Adding new sites and investigators
- Notification of serious breaches of the protocol
- Progress and safety reports
- Notifying the end of the study

The HRA website also provides guidance on these topics, which is updated in the light of changes in reporting requirements or procedures.
User Feedback

The Health Research Authority is continually striving to provide a high quality service to all applicants and sponsors. You are invited to give your view of the service you have received and the application procedure. If you wish to make your views known please use the feedback form available on the HRA website: http://www.hra.nhs.uk/about-the-hra/governance/quality-assurance/

HRA Training

We are pleased to welcome researchers and R&D staff at our training days – see details at http://www.hra.nhs.uk/hra-training/

17/SW/0212 Please quote this number on all correspondence

With the Committee’s best wishes for the success of this project.

Yours sincerely

Dr Denise Sheehan
Chair
Email:nrescommittee.southwest-exeter@nhs.net

Enclosures: “After ethical review – guidance for researchers”

Copy to: Ms Becky Ward, Imperial College London